Breaking

Sofwave Caps Strong Quarter: Net Profit Quadruples; Initial Order for 70 Systems in China

The medical aesthetics company's revenue grew 35% in the third quarter to $28.5 million • Recurring revenue from the company's systems rose 60% and accounted for nearly half of total revenue • The company expects to deliver an additional 60 systems to its distributor in China in the fourth quarter

The Tel Aviv Stock Exchange
The Tel Aviv Stock Exchange | Photo: Shutterstock

Sofwave Medical, which develops and markets systems for medical aesthetic treatments, released its financial results this morning for the third quarter of 2026, reporting revenue growth and a significant improvement in profitability.

The company's revenue totaled $28.5 million, up 35% from $21.1 million in the corresponding quarter last year. Net profit surged to approximately $4.1 million, compared with approximately $982 thousand in the corresponding period. Operating profit nearly tripled to $4.42 million.

One of the prominent growth drivers in the quarter was recurring revenue from use of the company's systems, which grew 60% to $13.3 million, approximately 47% of total revenue. At the same time, the gross profit margin rose to 76.6%, and the company recorded positive cash flow of approximately $2.8 million from operating activities.

Establishing a foothold in China

Alongside its financial results, Sofwave reported progress in its operations in China. After receiving regulatory approval to market its products in the country in September, the company received an initial order for 70 systems from local distributor HTDK. Ten systems were delivered during the third quarter, and the remaining 60 systems are expected to be delivered in the fourth quarter. The company did not disclose the financial value of the order.

Looking at the first nine months of the year, Sofwave's revenue totaled $82.9 million, up 41% from the corresponding period in 2025. Net profit during this period reached $7.9 million, compared with approximately $1.4 million in the first nine months of last year.

Key takeaways

  • Sofwave Medical reported third-quarter 2026 revenue of $28.5 million, up 35% from $21.1 million a year earlier.
  • Net profit rose to approximately $4.1 million, compared with approximately $982 thousand in the corresponding quarter last year.
  • Recurring revenue from use of the company's systems increased 60% to $13.3 million and accounted for approximately 47% of total revenue.
  • The company said gross profit margin rose to 76.6% and it generated positive operating cash flow of approximately $2.8 million.
  • In China, Sofwave received an initial order for 70 systems from distributor HTDK, with 10 delivered in the third quarter and 60 expected in the fourth quarter.

Questions and answers

How did Sofwave perform in the third quarter of 2026?
Sofwave reported revenue of $28.5 million, up 35% year over year, and net profit of approximately $4.1 million, versus approximately $982 thousand a year earlier. Operating profit nearly tripled to $4.42 million.
What was the main driver of Sofwave's growth?
Recurring revenue from use of the company's systems rose 60% to $13.3 million. That segment made up approximately 47% of total revenue.
What did Sofwave say about its China business?
After receiving regulatory approval to market its products in China in September, Sofwave got an initial order for 70 systems from local distributor HTDK. Ten systems were delivered in the third quarter, and the remaining 60 are expected in the fourth quarter.

Share this story

About the writer

TV10 Desk

Writes for TV10, Israel’s economic channel. This story was translated from the original Hebrew.

More stories by TV10 Desk

More for you